10x Genomics, Inc. (TXG) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 118.51M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 49.52M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 47.55M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 52.62M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $118.51M | (m) | $49.52M | $47.55M | $52.62M | (m) |
| 2026-03-31 | (m) | $113.60M | (m) | $49.56M | $39.03M | $53.49M | (m) |
| 2025-12-31 | (m) | $153.45M | (m) | $49.44M | $47.01M | $56.34M | (m) |
| 2025-09-30 | (m) | $147.32M | (m) | $49.58M | $43.78M | $61.96M | (m) |
| 2025-06-30 | (m) | $112.22M | (m) | $49.55M | $49.98M | $68.97M | (m) |
| 2025-03-31 | (m) | $107.90M | (m) | $49.84M | $52.55M | $74.71M | (m) |
| 2024-12-31 | $481.26M | $117.63M | $344.07M | $49.34M | $87.86M | $83.11M | 4.09× |
| 2024-09-30 | (m) | $121.23M | (m) | $0.00 | $83.53M | $94.05M | (m) |
| 2024-06-30 | (m) | $111.02M | (m) | $269.00K | $91.18M | $88.27M | (m) |
| 2024-03-31 | (m) | $108.73M | (m) | $16.03M | $91.31M | $83.19M | (m) |
| 2023-12-31 | $503.53M | $127.16M | $359.28M | $29.41M | $114.83M | $73.71M | 3.96× |
| 2023-09-30 | (m) | $104.72M | (m) | $45.64M | $103.85M | $80.92M | (m) |
| 2023-06-30 | (m) | $98.09M | (m) | $65.51M | $87.69M | $83.69M | (m) |
| 2023-03-31 | (m) | $112.01M | (m) | $85.97M | $77.94M | $82.31M | (m) |
| 2022-12-31 | $534.20M | $130.96M | $219.75M | $210.24M | $104.21M | $81.63M | 4.08× |
| 2022-09-30 | (m) | $126.86M | (m) | $218.44M | $83.55M | $78.63M | (m) |
| 2022-06-30 | (m) | $117.91M | (m) | $225.55M | $76.20M | $70.65M | (m) |
| 2022-03-31 | (m) | $94.45M | (m) | $226.84M | $76.53M | $63.70M | (m) |
| 2021-12-31 | (m) | $110.36M | $587.45M | (m) | $85.25M | $59.97M | (m) |
| 2021-09-30 | (m) | $100.38M | (m) | (m) | $78.43M | $51.14M | (m) |
| 2021-06-30 | (m) | $113.13M | (m) | (m) | $59.68M | $44.09M | (m) |
| 2021-03-31 | (m) | $120.55M | (m) | (m) | $57.41M | $38.51M | (m) |
| 2020-12-31 | (m) | $118.13M | $663.60M | (m) | $51.21M | $29.96M | (m) |
| 2020-09-30 | (m) | $145.57M | (m) | (m) | $36.03M | $25.12M | (m) |
| 2020-06-30 | (m) | $122.18M | (m) | (m) | $22.73M | $21.76M | (m) |
| 2020-03-31 | (m) | $59.07M | (m) | (m) | $30.85M | $19.36M | (m) |
| 2019-12-31 | (m) | $63.05M | $424.17M | (m) | $33.37M | $15.27M | (m) |
| 2019-09-30 | (m) | $48.24M | $427.44M | (m) | $26.15M | $13.30M | (m) |
| 2018-12-31 | (m) | $32.36M | $65.08M | (m) | $28.09M | $8.57M | (m) |
| 2017-12-31 | (m) | (m) | $47.86M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.